TOP > 外国特許検索 > THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES

THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES NEW

外国特許コード F190009684
整理番号 (S2017-0671-N0)
掲載日 2019年1月22日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP016668
国際公開番号 WO 2018199109
国際出願日 平成30年4月24日(2018.4.24)
国際公開日 平成30年11月1日(2018.11.1)
優先権データ
  • 特願2017-085253 (2017.4.24) JP
発明の名称 (英語) THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES NEW
発明の概要(英語) Provided is a therapeutic agent, a preventive agent, or the like that is for diseases caused by accumulation of abnormal protein and that contains a compound represented by general formula (I) (in the formula, R1 and R2 each represent a hydrogen atom or a hydroxyl group (either R1 or R2 is a hydroxyl group)).
従来技術、競合技術の概要(英語) BACKGROUND ART
Alzheimer's disease, Parkinson's disease, motor neuron disease and the like of the neurodegenerative disease is, modified by a particular neuron is dropped, and progressive cognitive impairment and motor impairment refractory exhibits.Various neurodegenerative diseases and pathological feature is common, and an accumulation of abnormal protein, as this accumulation and neurodegenerative disease of the central thought.However, the neuron and its accumulated around the abnormal protein, neuronal dysfunction and how to induce cell death is unknown or many points, yet prevent the underlying treatment condition itself has not been established.
Fuzzy is automatic, the ubiquitin-proteasome system (UPS) as well as the, degradation of the mutant proteins within cells is an important system (non-patent document 1).In recent years, studies on the molecular mechanism of the fuzzy automatic and performed, in particular, fuzzy auto master regulator of transcription factor TFEB (transcription factor EB) and an auto-activation of the compound according to the fuzzy many research has been performed (non-patent document 2).In recent years, the functions of a fuzzy reduction auto, various neurodegenerative diseases has been suggested to be involved in the pathology from, the auto-fuzzy is a neurodegenerative disease as important therapeutic targets of attention (Non-Patent Document 3).Current, as the automatic activation of a fuzzy mechanism, while being accumulated in the knowledge path mTORC of the camera, the image is still in its entirety remains unknown in many cases.In addition, by the selective decomposition of the protein in the pathogenesis of fuzzy auto picture of the mechanism has not been resolved, methods of treating disorders using such a mechanism is in the current stage of development.The inventors of the present invention, the active ingredient to this crude (peony as an effective ingredient paeoniflorin, soybean or the like contains a large number of plant genistein) the auto-activation and of using the fuzzy, the studies of the molecular mechanisms, as well as the effective component in the activation of the auto-fuzzy, spinal muscular atrophy (SBMA) sphere to study therapeutic effects of transgenic mouse model has been performed (non-patent document 4, 5).These compounds, while the efficacy as a therapeutic, or via a plurality of routes, there is room for improvement of its pharmacologic effect has been found and the like.
Kaempferol is, tea, fruits, vegetables, beans and the like of many plants including the natural flavonol of the present invention.Kaempferol is, anti-oxidants, anti-inflammatory, anti-cancer, anti-diabetic, antiosteoporosis, and anti-allergic activity has a variety of pharmacological effects, among other things, is a strong anti-oxidation effect is noticed (non-patent document 6, 7).In addition, by binding to, NADPH oxidase (NOX) kaempferol is, there is a possibility that can prevent neural degeneration has been suggested (Non-Patent Document 8).Further, kaempferol-solvent including, a smoker's pancreatic cancer and the like can be suppressed the occurrence of possibility has been suggested (Non-Patent Document 9).
Luteolin is, celery, green peppers, many plant shiso (perilla) contained in the food kind of a flavone of natural (non-patent document 10).Luteolin also, has the effect of various pharmacological shown, blood cholesterol-lowering effect (Non-Patent Document 11), (Patent Document 12) anti-oxidation, anti-inflammatory effects and the like (Patent Document 12) have been reported.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, JAPAN
  • 発明者(英語)
  • ADACHI, Hiroaki
  • HUANG, Zhe
国際特許分類(IPC)

PAGE TOP

close
close
close
close
close
close